R esearch has established that stenosis comprises 2 main processes, neointimal hyperplasia and vessel remodeling. 1 In particular, experimental studies show that inflammatory cell infiltration 2 and proliferation of vascular smooth muscle cells (VSMCs) are involved in neointimal hyperplasia. 1, 3 However, several clinical trials with systemic anti-inflammatory approaches (eg, steroid or tranilast) failed to show protection from restenosis. 4, 5 Importantly, both experimental and clinical studies suggest that VSMCs proliferation is critical to neointimal hyperplasia after mechanical injury, including wire-, balloon-, and stent-induced injury. 3 Either mechanical injury or growth factors trigger VSMCs to progress through the G1-S transition of the cell cycle. 6 The different phases of the eukaryotic cell cycle are regulated by a series of protein complexes composed of cyclins, catalytic cyclin-dependent kinases (CDKs), and their cyclin-dependent kinase inhibitors (CKIs; p27 Kip1 , p21 Cip1 , and p16
Ink4
). 7 
p27
Kip1 is a key member of the Cip/Kip family of CKIs that functions to negatively regulate cyclin-Cdk holoenzymes such as cyclin E-Cdk2 complexes in the nucleus, resulting in cell cycle arrest at the G1/S transition. 7 Constitutively expressed in normal arteries, p27
Kip1 expression is downregulated after arterial injury and inversely correlated with VSMC proliferation. 6 Gene transfer of either p27 Kip1 or p21 Cip1 into balloon-injured arteries produces a significant reduction in VSMC proliferation and neointimal thickening. 6, 8, 9 Importantly, loss of p27
Kip1 results in a prominent vascular phenotype characterized by markedly increased neointimal thickening after mechanical arterial injury. 10 These findings strongly suggest that p27
Kip1 is a key regulator of VSMC proliferation in vascular disease.
Adenosine monophosphate-activated protein kinase (AMPK) exists as a heterotrimeric complex consisting of a catalytic subunit, ␣, and 2 regulatory subunits, ␤ and ␥. 11 AMPK activation leads to cell cycle arrest in tumor cells, 12 fibroblasts, and neural stem cells. 13 Recently, Igata et al 14 reported that 5-aminoimidazole-4-carboxamide ribonucleoside (AICAR), an activator of AMPK, inhibits platelet-derived growth factor-BB (PDGF-BB)-and fetal calf serum (FCS)-induced human VSMC proliferation significantly. Additionally, AMPK activation by AICAR inhibits angiotensin II-stimulated rat VSMC proliferation. 15 Subcutaneous injection of AICAR for 2 weeks suppresses neointimal formation after transluminal mechanical injury of the rat femoral artery. 15 Consistent with this, AMPK activation inhibits VSMC hypertrophy induced by thromboxane receptor activation. 16 Moreover, reduction of AMPK␣2 increases atherosclerosis in low-density lipoprotein receptor-deficient mice. 17 However, the contribution of the individual isoforms, AMPK␣1 and AMPK␣2, to vascular remodeling is unclear, and the mechanism by which AMPK regulates VSMC cell cycle progression remains to be elucidated. We show that loss of AMPK␣2 but not AMPK␣1 activates NF-B2, which upregulates the E3 ligase Skp2. p27
Kip1 is subsequently downregulated, resulting in increased VSMC proliferation, which contributes to neointima hyperplasia.
Methods
An expanded Methods section is available in the online Data Supplement at http://circres.ahajournals.org.
Animals
AMPK␣1 and AMPK␣2 homozygous knockout (AMPK␣1 Ϫ/Ϫ or AMPK␣2 Ϫ/Ϫ ) mice were generated on a C57BL/6J background as described previously. 17 Wild-type (WT) mice, and corresponding littermates, served as controls. All animal experiments were approved by the Institutional Animal Care and Use Committee at the University of Oklahoma Health Sciences Center.
Isolation of Mouse VSMCs
Mouse VSMCs were isolated from cultured explants of aortas from 8-to 10-week-old WT, AMPK␣1
Ϫ/Ϫ , and AMPK␣2 Ϫ/Ϫ mice as described. 18 
Wire Injury of Carotid Artery
The carotid arteries of 8ϳ9-week-old mice were injured with wire just proximal to the carotid bifurcation as described previously. 19 Animals were allowed to recover and carotid arteries were harvested 2 weeks after the injury. Carotid arteries were fixed in 4% formalin overnight. Sections were stained with hematoxylin and eosin, and immunohistochemistry was performed using various antibodies as described previously. 20 
Quantitative Real-Time Reverse Transcription Polymerase Chain Reaction
Targeted gene expression levels were probed by quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR) using the corresponding primers (Online Data) as described previously. 21 
Immunoprecipitation and Western Blotting
Cell lysis, immunoprecipitation, and immunoblotting were performed as previously described. 20, 22 Immunoprecipitation and immunoblotting experiments were conducted using 800 and 50 g of protein lysate, respectively, unless otherwise indicated. Equal loading of protein was verified by immunoblotting with anti-␤-actin antibody.
Cellular DNA Synthesis and Cell Cycle Analysis
The VSMC proliferation capacity was assessed by 5-bromo-2Ј-deoxyuridine (BrdU) incorporation and flow cytometry analysis.
Statistical Analysis
Results are expressed as meanϮSD. Statistical significance for comparisons between 2 groups was calculated using the 2-tailed Student t test. To assess comparisons between multiple groups, ANOVA followed by the Bonferroni procedure was performed using the Graph-Pad Prism 4 program (GraphPad Software, Inc, San Diego, CA). A probability value of Ͻ0.05 was considered to be statistically significant.
Results

AMPK␣2 Knockout Enhances VSMC Proliferation In Vitro
First, we sought to investigate whether AMPK␣2 is involved in VSMC proliferation. Cell proliferation assays demonstrated that primary VSMCs isolated from AMPK␣2 Ϫ/Ϫ mice exhibited greater proliferation after 2 and 3 days in culture compared with WT or AMPK␣1 Ϫ/Ϫ cells ( Figure 1A ). Consistent with this, incorporation of the thymidine analog BrdU, which indicates DNA synthesis, was significantly greater in AMPK␣2 Ϫ/Ϫ VSMCs ( Figure 1B ). To test whether this enhanced growth is associated with cell-cycle dysregulation, serum-starved VSMCs were cultured in complete medium for 16 hours and cell cycle progression was analyzed by flow cytometry after staining with propidium iodide. As expected, the proportion of S-phase cells increased whereas the number of G1-phase cells decreased in AMPK␣2 Ϫ/Ϫ VSMCs compared with either WT or AMPK␣1
Ϫ/Ϫ cells ( Figure 1C ), suggesting that AMPK␣2 knockout promotes the G1-S transition.
AMPK␣1 Is a Major Isoform of AMPK␣ in Isolated VSMCs
Next, we examined the relative contribution of AMPK␣2 and AMPK␣1 to the total AMPK␣ activity. Thus, immunoblotting was performed to assess the phosphorylation of AMPK␣ (Thr172) and acetyl-coA carboxylase (ACC, Ser79), which is an indicator of AMPK activity, 12, 23 in WT, AMPK␣1
Ϫ/Ϫ , and AMPK␣2 Ϫ/Ϫ VSMCs. As expected, AMPK␣1 and AMPK␣2 were not detected in AMPK␣1 Ϫ/Ϫ and AMPK␣2
Ϫ/Ϫ
VSMCs, respectively ( Figure 1D ). Although total AMPK␣ protein levels in VSMCs from AMPK␣1 Ϫ/Ϫ mice, which presumably consists of AMPK␣2, was reduced to Ϸ15% that of WT cells, no compensatory upregulation of the AMPK␣2 isoform was observed ( Figure 1D and 1E), which is in line with the reported results from mouse aortic homogenates. 24 were barely detectable in AMPK␣1 Ϫ/Ϫ VSMCs. In contrast, expression of total AMPK␣ protein in VSMCs from AMPK␣2 Ϫ/Ϫ mice, which presumably consists of AMPK␣1 protein, was decreased slightly to Ϸ85% that of WT, no compensatory upregulation of the AMPK␣1 isoform was observed ( Figure 1D and 1E ). In addition, both AMPK␣ and ACC phosphorylation in AMPK␣1 Ϫ/Ϫ VSMCs were reduced to approximately 5% and 10% of WT, respectively ( Figure  1D and 1E). These results imply that AMPK␣1 may account for approximately 85% of total AMPK␣ activity and that AMPK␣1 is the predominant isoform in mouse VSMCs.
AMPK␣2 Deletion/Inactivation Reduces p27
Kip1
Levels in VSMCs
As CKIs, p27
Kip1 and p21 Cip1 play important roles in neointimal hyperplasia. 8 -10,26 -28 Therefore, we investigated whether either AMPK␣2 or AMPK␣1 deletion altered their expression. The level of p27
Kip1 protein was decreased dramatically in AMPK␣2 Ϫ/Ϫ VSMCs compared with WT and AMPK␣1
Ϫ/Ϫ VSMCs ( Figure 2A ), whereas the level of p27
Kip1
-T187 phosphorylation was increased significantly in AMPK␣2 Ϫ/Ϫ VSMCs (Online Figure I, A) . Paradoxically, the level of p27 Kip1 mRNA was elevated in both AMPK␣2
Ϫ/Ϫ and AMPK␣1 Ϫ/Ϫ VSMCs ( Figure 2B ). In contrast, p21
Cip1 protein levels were increased significantly in AMPK␣2 Ϫ/Ϫ VSMCs compared with WT or AMPK␣1 Ϫ/Ϫ VSMCs (Figure 2A ), which may be permissive to VSMC proliferation. 29 To validate the effect of AMPK␣ inhibition on p27
Kip1 reduction in human VSMCs, we performed siRNA knockdown of either AMPK␣2 or AMPK␣1 to test the individual contribution of each isoform in reducing p27 Kip1 expression in human VSMCs. As depicted in Figure 2C , transfection of AMPK␣2-specific siRNA reduced the levels of AMPK␣2 and total AMPK␣ protein by 80% and 10% in human VSMCs, respectively. Transfection of AMPK␣1-specific siRNA suppressed AMPK␣1 and total AMPK␣ levels by 90% and 75%, respectively. Interestingly, the level of p27
Kip1 protein was reduced significantly in AMPK␣2 siRNA-transfected human VSMCs compared with cells transfected with either control siRNA or AMPK␣1 siRNA ( Figure 2C ). Compound C (CpC), a potent AMPK inhibitor, 30 reduced the levels of phosphorylated AMPK␣ and ACC, as well as p27 Kip1 ( Figure  2D ), in human VSMCs. Collectively, these results demonstrate that AMPK␣2 deletion or inhibition resulted in p27 Kip1 reduction in both mouse and human VSMCs.
Reduced p27
Kip1 Levels in AMPK␣2 ؊/؊ VSMCs Occur Through Proteasome-Mediated Degradation Next, we examined whether the reduced p27
Kip1 expression observed in AMPK␣2 Ϫ/Ϫ VSMCs resulted from proteasomemediated degradation. As shown in Figure 3A and 3B, treatment for 8 hours with 10 mol/L MG132, a potent inhibitor of the 26S proteasome, blocked the reduction in p27
Kip1 protein levels and caused accumulation of poly-ubiquitinated p27 Kip1 (Online Figure I 
, B) in AMPK␣2
Ϫ/Ϫ VSMCs. AMPK␣-Thr172 and ACCSer79 phosphorylation remained unchanged. Likewise, MG132 treatment increased p21
Cip1 protein levels (Online Figure I , B). Furthermore, p27
Kip1 in AMPK␣2 Ϫ/Ϫ VSMCs had a shorter half-life (2 hours) than that in WT VSMCs (5 hours) ( Figure  3C ). In addition, MG132 attenuated the effects of compound C on p27
Kip1 reduction in human VSMCs ( Figure 3D and 3E). Taken together, these data suggest that the ubiquitin-proteasome pathway is involved in p27
Kip1 degradation in AMPK␣2-deleted/ inhibited mouse and human VSMCs.
Skp2 Is Elevated in AMPK␣2
؊/؊ VSMCs
Because the Skp1/Cullin/F-box protein (SCF)-type ubiquitin ligase complex that contains Skp2 is the main rate-limiting regulator of p27 Kip1 ubiquitylation and degradation in various cell types, 31, 32 including VSMCs, 28, 33 we assessed Skp2 expression in mouse VSMCs. As depicted in Figure 4A , the abundance of Skp2 mRNA was increased in AMPK␣2 Ϫ/Ϫ VSMCs compared with WT and AMPK␣1 Ϫ/Ϫ VSMCs. Moreover, the levels of Skp2 protein were augmented in AMPK␣2 Ϫ/Ϫ mouse VSMCs ( Figure 4B ). However, no changes were detected in the expression of the Skp2-associated SCF Skp2 subunits Cullin1, and Skp1 ( Figure 4B ). CpC treatment also enhanced Skp2 protein levels dramatically in human VSMCs ( Figure 4C ). Overall, these results indicate that Skp2 is upregulated by AMPK␣2 deletion or inhibition in mouse and human VSMCs. , and WT VSMCs, which is consistent with reported results in rat VSMCs. 28 Likewise, siRNA-mediated knockdown of Skp2 repressed endogenous Skp2 expression significantly in human VSMCs by 85% ( Figure 5B ). Furthermore, Skp2-specific siRNA but not control siRNA reversed the CpC-induced reduction of p27
Kip1 protein levels ( Figure 5B ). Taken together, p27
Kip1 reduction in the absence of AMPK␣2 in VSMCs is mediated by Skp2.
In addition, our data demonstrate that levels of the E2 ubiquitin-conjugating enzyme Cdc34 34 involved in p27 ubiquitination, 35 was elevated significantly in AMPK␣2 Ϫ/Ϫ and AMPK␣1 Ϫ/Ϫ VSMCs ( Figure 5C ). Moreover, interaction between Cdc34 and Skp2 was enhanced due to AMPK␣ deletion ( Figure 5D ). Because p27
Kip1 reduction was only observed in AMPK␣2 Ϫ/Ϫ VSMCs with Skp2 induction, these results established that Skp2 but not Cdc34 may function as the determining factor for accelerated p27
Kip1 turnover in AMPK␣2 Ϫ/Ϫ VSMCs. To determine whether the elevated VSMCs proliferation observed in AMPK␣2 null mice is mediated by Skp2, we transfected WT and AMPK␣2
Ϫ/Ϫ VSMCs with either Skp2-specific or control siRNA and then measured BrdU incorporation. AMPK␣2
Ϫ/Ϫ VSMCs exhibited greater BrdU incorpora- tion than WT VSMCs transfected with control siRNA ( Figure  5E ). Interestingly, this effect was blocked by transfection with Skp2-specific siRNA ( Figure 5E ). These findings indicate that upregulation of Skp2 is responsible for the elevated proliferation of AMPK␣2 Ϫ/Ϫ VSMCs.
Upregulation of Skp2 by AMPK␣2 Knockout Is Dependent on NF-B2
The NF-B2 transcription factor reportedly regulates Skp2 gene expression. 36, 37 Interestingly, IB␣ was reduced by 30% in AMPK␣2 Ϫ/Ϫ VSMCs ( Figure 6A ). Moreover, nuclear translocation of p52 and RelB was detected in AMPK␣2 Ϫ/Ϫ VSMCs ( Figure 6B ), whereas levels of p50 NF-B1 in the nucleus were comparable (Online Figure II, A) . Furthermore, NF-B2/DNA binding activity was increased in AMPK␣2 Ϫ/Ϫ VSMCs ( Figure  6C ). These results was in line with a very recent report, NF-B p52 is constitutively activated in AMPK␣ Ϫ/Ϫ MEFs. 38 Interestingly, AMPK␣2 deletion clearly increased the binding of p52 to the Skp2 promoter ( Figure 6D ).
To study whether p52 contributes to Skp2 upregulation, we transfected WT, AMPK␣1 Ϫ/Ϫ , and AMPK␣2 Ϫ/Ϫ VSMCs with either p52-specific or control siRNA. Western blot analysis confirmed efficient knockdown of p52 protein after transfection with p52-specific siRNA ( Figure 6E ). Transfection with p52-specific but not control siRNA attenuated Skp2 induction and reversed p27
Kip1 reduction in AMPK␣2 Ϫ/Ϫ VSMCs. Addition- 
ally, NF-B inhibitor also inhibited Skp2 induction and blocked p27
Kip1 reduction (Online Figure II, B) . p52 siRNA did not completely block Skp2 expression, because other transcription factors including STAF (selenocysteine tRNA gene transcription-activating factor) mediate Skp2 expression in VSMCs. 39 Taken together, Skp2 upregulation and the resulting p27
Kip1 reduction in AMPK␣2 Ϫ/Ϫ VSMCs is mediated by p52.
AMPK␣2 Deletion Exacerbates Neointimal Formation In Vivo
To determine the effects of AMPK␣ deletion on vascular remodeling in vivo, we performed carotid artery wire injury in WT, AMPK␣1 Ϫ/Ϫ , and AMPK␣2 Ϫ/Ϫ mice ( Figure 7A ). After injury, WT mice exhibited a substantial increase in the neointima as indicated by the area of the space between the lumen and internal elastic lamina (9.51Ϯ0.83ϫ10 3 m 2 ). The injured carotid arteries of AMPK␣1 Ϫ/Ϫ mice exhibited a neointimal area (9.16Ϯ0.96ϫ10 3 m 2 ) similar to that of WT mice. In contrast, the neointimal area (38.04Ϯ5.6ϫ10 3 m 2 ) of AMPK␣2 Ϫ/Ϫ mice was increased (PϽ0.01) compared with that of WT and AMPK␣1 Ϫ/Ϫ mice. However, the medial area of the injured carotid arteries did not differ between the groups. Therefore, the intima-to-media ratio was elevated substantially in injured carotid arteries from AMPK␣2 Ϫ/Ϫ mice (2.44Ϯ0.05) compared with either WT or AMPK␣1
Ϫ/Ϫ mice (0.56Ϯ0.20 and 0.58Ϯ0.12, respectively; PϽ0.01; Figure 7B ). Collectively, these data suggest that AMPK␣2 is primarily responsible for antineointima formation. Thus, AMPK␣2 inhibition and its downstream signaling pathway may be more critical to VSMCs proliferation after vascular injury.
Next, we determined which cell types compose the increased neointima area. Wire-injured vessels were stained with antibodies against SMC ␣-actin (a marker of VSMCs), 40 CD68 (a marker of macrophages), 41 or CD45 (a maker of neutrophils). 42 Immunohistochemical staining demonstrated that VSMCs are the predominant cell type present in the neointima area ( Figure 7C) .
To test the effects of wire injury on cell proliferation in vivo, we stained the neointima for proliferating cell nuclear antigen (PCNA). After wire injury of the carotid artery, PCNA staining increased in the neointima of AMPK␣2 Ϫ/Ϫ but not AMPK␣1 Ϫ/Ϫ mice compared with WT animals ( Figure 7D ). PCNA staining in the medial area was comparable between WT and AMPK␣2 Ϫ/Ϫ mice. These findings suggest that VSMCs proliferation in AMPK␣2 Ϫ/Ϫ mice promotes neointima formation after vascular injury.
Finally, we assessed whether p52, Skp2, and p27 Kip1 levels are altered in the neointima area of AMPK␣2 Ϫ/Ϫ mice. After injury, p52 staining increased in the nucleus of neointimal VSMCs of AMPK␣2 Ϫ/Ϫ but not AMPK␣1 Ϫ/Ϫ mice compared with WT animals ( Figure 8A and 8B) . No rabbit IgG as the substitute for antip52 primary antibody produced any staining on the sections (Online Figure III) . Skp2 staining also increased Ϫ/Ϫ , and AMPK␣2 Ϫ/Ϫ VSMCs were transfected with either control or Skp2-specific siRNA (100 nmol/L) for 48 hours; top, p27 Kip1 and Skp2 levels were assessed by Western blot. This blot is representative of 4 blots obtained from 4 independent experiments; bottom, quantification of data; nϭ4; *PϽ0.01 versus WT/control siRNA; †PϽ0.001 versus ␣2 Ϫ/Ϫ /control siRNA; #PϽ0.05 versus corresponding control siRNA treatment. B, p27
Kip1 reduction by AMPK␣ inhibition is mediated by Skp2. Human VSMCs were transfected with either control or Skp2-specific siRNA (100 nmol/L) for 48 hours and then left untreated or were treated with 15 mol/L CpC for 6 hours. p27
Kip1 and Skp2 levels were assessed by Western blot. This blot is representative of 3 blots obtained from 3 independent experiments; nϭ3; *PϽ0.01 versus vehicle; †PϽ0.001 versus CpC/control siRNA; #PϽ0.05 versus vehicle/control siRNA. C, Levels of Cdc34, an E2 ubiquitin-conjugating enzyme, is elevated in AMPK␣ Ϫ/Ϫ VSMCs; top, Cdc34 protein levels in WT, AMPK␣1 Ϫ/Ϫ , and AMPK␣2 Ϫ/Ϫ mouse VSMCs were analyzed by Western blot; bottom, quantification of the Western blot data. This blot is representative of 5 blots from 5 independent experiments; nϭ5; *PϽ0.001 versus WT; †PϽ0.05 versus WT. D, AMPK␣ deletion augments the interaction of Skp2 with Cdc34 in mouse VSMCs. Skp2 was immunoprecipitated, and Cdc34 was detected by Western blot; nϭ3; *PϽ0.05 versus WT. E, Increased DNA synthesis in AMPK␣2
VSMCs is mediated by Skp2. BrdU incorporation was measured in WT and AMPK␣2 Ϫ/Ϫ VSMCs transfected with either control or Skp2-specific siRNA; nϭ3; *PϽ0.05 versus WT/control siRNA; †PϽ0.05 versus respective control siRNA treatment.
( Figure 8A and 8C) , which is consistent with Skp2 expression is increased in neointimal lesions reported by Wu et al 28 ; however, p27
Kip1 was reduced in AMPK␣2 Ϫ/Ϫ mice compared with either WT or AMPK␣1 Ϫ/Ϫ animals ( Figure 8A and 8C) . Moreover, the intima-to-media ratio of wire-injured carotid artery in WT mice was modestly but significantly reduced by the antidiabetes drug metformin, an AMPK activator, 30 compared with vehicle treatment ( Figure 8D ). Ϫ/Ϫ , and AMPK␣2 Ϫ/Ϫ mouse was immunoprecipated with an antip52, or rabbit IgG as a negative control. Precipitated DNA or 10% of the chromatin input was amplified with gene-specific primers for mouse Skp2 promoter. This result is representative of 3 independent experiments. E, siRNA-mediated knockdown of p52 abolishes Skp2 induction and p27
Kip1 reduction in AMPK␣2 Ϫ/Ϫ VSMCs.
WT, AMPK␣1
Ϫ/Ϫ , and AMPK␣2 Ϫ/Ϫ mouse VSMCs were transfected with either p52-specific or control siRNA before assessment of Skp2, p27 Kip1 , and p52 by Western blot; top, this blot is representative of 3 independent experiments; bottom, quantification of the Western blot data; nϭ3; *PϽ0.001 versus WT/control siRNA; †PϽ0.01 versus ␣2 Ϫ/Ϫ /control siRNA; #PϽ0.05 versus corresponding control siRNA treatment. Ϫ/Ϫ , and AMPK␣2 Ϫ/Ϫ mice were stained with antibodies against PCNA at 14 days after wire injury. Scale bar, 50 m; nϭ6 in each group; *PϽ0.01 versus WT.
Discussion
In the present study, we have shown that AMPK␣2 but not AMPK␣1 deletion mediates neointimal formation after vascular injury. The mechanism underlying this process is due to a novel pathway in which VSMCs proliferation is elevated as a result of p27
Kip1 downregulation, which is controlled by upregulation of Skp2 through NF-B2 ( Figure 8E ). These findings indicate that AMPK␣2 is an important mediator for VSMCs function during the postnatal period and suggest that therapy that modulates AMPK␣2 signaling in VSMCs may be beneficial in treating vascular proliferative diseases.
The most important finding of this study is that we have for the first time unveiled that AMPK␣2 deletion activates NF-B2, which upregulates ubiquitin E3 ligase Skp2, and consequent p27
Kip1 downregulation, which contributes to neointima formation. Several lines of evidence are consistent with the hypothesis. First, AMPK␣2 deletion profoundly activated NF-B2 (increased p52 nuclear translocation and DNA binding activity). Second, Skp2 mRNA and protein levels were significantly elevated in AMPK␣2 Ϫ/Ϫ VSMCs. Third, AMPK inhibition with Compound C treatment markedly upregulated Skp2 proteins in human VSMCs; Fourth, proliferating human VSMCs with lower pAMPK␣-T172 had much more Skp2 proteins than overconfluent (quiescent) human VSMCs with higher pAMPK␣-T172 (Online Figure IV, A, and IV, B) . Fifth, p52 siRNA transfection notably eliminated Skp2 upregulation and p27
Kip1 downregulation in AMPK␣2 Ϫ/Ϫ VSMCs. Sixth, siRNA-mediated knockdown of Skp2 normalized the elevated DNA synthesis in AMPK␣2 Ϫ/Ϫ VSMCs. Taken together, these findings demonstrate that AMPK␣2 deletion/inactivation elevates NF-B2-mediated Skp2, which potently modulates VSMCs activation and function through p27
Kip1 reduction. Recently, Skp2 Ϫ/Ϫ mice have been shown to develop significantly smaller neointima areas than WT mice after carotid ligation. 43 Our results and previous reports 26, 28, 43 strongly suggest that Skp2 is a viable target for vascular therapies aimed at inhibiting VSMC proliferation, including antiatherogenesis and antirestenosis.
Although Skp2 has several downstream substrates, including p27
Kip1 and p21
Cip1
, 29, 44 they have different profiles in AMPK␣2 Ϫ/Ϫ VSMCs. We found the loss of AMPK␣2 downregulated p27
Kip1 through upregulation of Skp2. In contrast, p21
Cip1 was upregulated in these knockout mice. These results extend the observations by Wu et al that dominant-negative Skp2 upregulates p27 Kip1 , but not p21
. 43 Moreover, serum stimulation decreased p27
Kip1 and increased p21 Cip1 in AMPK␣2 Ϫ/Ϫ VSMCs within 24 hours (Online Figure V) . Our data support the fact that serum enhances p21
Cip1 expression, which was reported by Bond group 29 and Sata et al 27 These results imply that p21
Cip1 is required for VSMCs survival and proliferation. 29 Hence, different CKIs may have different functions in the cell cycle of VSMCs. Skp2 overexpression downregulates p21 Cip1 , whereas overexpression of F-box deleted dominant-negative Skp2 (DN-Skp2) upregulates p21
Cip1 in rat VSMC in vitro. 29 Here, Skp2 induction was not associated with a corresponding p21
Cip1 reduction in AMPK␣2 Ϫ/Ϫ VSMCs, which may due to p21
Cip1 regulation by a Skp2-independent mechanism. 45 NF-B2 was superactivated in AMPK␣2 Ϫ/Ϫ VSMCs, so efficient p52 silencing or treatment with an NF-B inhibitor significantly blocks the induction of Skp2 in AMPKa2 Ϫ/Ϫ cells, with less effect of NF-B silencing on Skp2 in WT cells. These results imply that other transcription factors, including STAF, 39 would control basic Skp2 expression in VSMCs, whereas NF-B p52 may control Skp2 upregulation under pathological condition associated with AMPK inhibition. Importantly, NF-B2 and Skp2 were regulated differentially by AMPK␣2 and AMPK␣1, suggesting that AMPK␣ exerts Kip1 (brown) in wire-injured carotid artery. All sections were counterstained with hematoxylin and eosin to detect nuclei (blue). Arrow indicates p52-nuclear positive cells. Scale bar, 50 m. B, Quantification of the nuclear p52-positive staining in neointima; nϭ6 in each group; *PϽ0.01 versus WT. C, Quantitative analysis of Skp2 and p27
Kip1 staining in neointima; nϭ6 in each group; *PϽ0.01 versus WT. D, The intima/media (I/M) area ratio was significantly less in mice treated with metformin than in controls; nϭ5 in each group; *PϽ0.05 versus vehicle. E, Proposed mechanism for elevated neointima proliferation in AMPK␣2 Ϫ/Ϫ mice.
isoform-specific functions possibly due to their distinct subcellular localization. 46 In particular, AMPK␣1 resides predominantly in the non-nuclear fraction, whereas AMPK␣2 is localized to both the nonnuclear fractions and the nucleus, 47 where it plays a role in transcriptional regulation. 48 Additionally, a nuclear localization signal presenting in AMPK␣2 but not in AMPK␣1 isoform may drive AMPK␣2 nuclear translocation. 49 How AMPK regulates NF-B2 activation warrants further investigation. In summary, we have shown that AMPK␣2 deletion/inhibition is critical for neointimal formation after vascular injury. AMPK␣2 deletion/inhibition enhances VSMC proliferation and may emerge as an important therapeutic target in vascular diseases involving excessive VSMC activation, such as restenosis, arteriosclerosis, and transplant-associated arteriopathy. The identity of the downstream targets of AMPK␣2 and the manner in which they regulate AMPK␣2-mediated VSMC function remain to be further elucidated.
